STTK

Shattuck Labs, Inc. [STTK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

STTK Stock Summary

Top 10 Correlated ETFs

STTK


Top 10 Correlated Stocks

STTK


In the News

10:53 26 Mar 2023 STTK

Shattuck Labs, Inc. (STTK) Q4 2022 Earnings Call Transcript

Shattuck Labs, Inc. (NASDAQ:STTK ) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Executive Officer and Scientific Co-Founder Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Marc Frahm - Cowen Yigal Nochomovitz - Citi Zhiqiang Shu - Berenberg Operator Good afternoon, ladies and gentlemen. Welcome to the Shattuck Labs Fourth Quarter and Full Year 2022 Earnings Conference Call.

07:00 26 Mar 2023 STTK

Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.

06:47 26 Mar 2023 STTK

Shattuck Labs, Inc. (STTK) Q3 2022 Earnings Call Transcript

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreiber - Chief Executive Officer Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Gil Blum - Needham & Company Carly Kenselaar - Citi Kaveri Pohlman - BTIG Zhiqiang Shu - Berenberg Operator Good afternoon, everyone, and welcome to Shattuck Labs Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

04:30 26 Mar 2023 STTK

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.

04:30 26 Mar 2023 STTK

Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12

AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC's 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston.

10:32 26 Mar 2023 STTK

Should You Buy Shattuck Labs (STTK) Ahead of Earnings?

Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

10:32 26 Mar 2023 STTK

Why Earnings Season Could Be Great for Shattuck Labs (STTK)

Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

08:21 26 Mar 2023 STTK

Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The first poster will highlight preclinical data from the company's GADLEN™ platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company's ARC® platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation.

05:00 26 Mar 2023 STTK

Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference

AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in the 11th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022.

08:30 26 Mar 2023 STTK

Shattuck Labs Announces Participation in Upcoming January Investor Conferences

AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.

STTK Financial details

Company Rating
Neutral
Market Cap
128.62M
Income
-101.95M
Revenue
652K
Book val./share
4.16
Cash/share
3.81
Dividend
-
Dividend %
-
Employees
85
Optionable
No
Shortable
Yes
Earnings
09 May 2023
P/E
-1.26
Forward P/E
-
PEG
-0.1
P/S
196.94
P/B
0.73
P/C
0.8
P/FCF
-1212122.79
Quick Ratio
6.46
Current Ratio
7.39
Debt / Equity
0.17
LT Debt / Equity
0.02
-
-
EPS (TTM)
-2.41
EPS next Y
-
EPS next Q
-
EPS this Y
125.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
37.46%
Revenue last 5Y
-50.72%
Revenue Q/Q
83.96%
EPS Q/Q
3.45%
-
-
-
-
SMA20
-32.74%
SMA50
7.09%
SMA100
7.47%
Inst Own
48.09%
Inst Trans
-0.59%
ROA
-50%
ROE
-48%
ROC
-0.57%
Gross Margin
8%
Oper. Margin
-15848%
Profit Margin
-15636%
Payout
-
Shs Outstand
42.45M
Shs Float
28.29M
-
-
-
-
Target Price
12
52W Range
1.85-5.82
52W High
-39.4%
52W Low
+203%
RSI
40.16
Rel Volume
0.17
Avg Volume
45.06K
Volume
7.73K
Perf Week
8.21%
Perf Month
-31.45%
Perf Quarter
12.22%
Perf Half Y
7.45%
-
-
-
-
Beta
1.20458
-
-
Volatility
0.09%, 0.74%
Prev Close
0%
Price
3.03
Change
-0.98%

STTK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
1.490.660.6400.02
Net income per share
-0.49-1.59-2.360-2.41
Operating cash flow per share
-0.46-1.39-2.17-1.350
Free cash flow per share
-0.54-1.43-2.22-1.350
Cash per share
4.012.621.636.383.81
Book value per share
-0.74-2.319.986.454.16
Tangible book value per share
-0.74-2.319.986.454.16
Share holders equity per share
-0.74-2.319.986.454.16
Interest debt per share
0.170000.1
Market cap
291.1M291.1M812.67M358.75M97.47M
Enterprise value
259.46M284.09M654.77M266.48M54.29M
P/E ratio
-39.4-12.14-22.20-0.96
Price to sales ratio
12.9729.4481.810149.5
POCF ratio
-42.17-13.88-24.14-6.28-1.03M
PFCF ratio
-36.02-13.57-23.63-6.28-918.57K
P/B Ratio
-26.27-8.432.621.320.55
PTB ratio
-26.27-8.432.621.320.55
EV to sales
11.5628.7365.91083.27
Enterprise value over EBITDA
-57.63-12.12-18.2-5.89-0.53
EV to operating cash flow
-37.59-13.54-19.45-4.67-574.56K
EV to free cash flow
-32.11-13.25-19.04-4.67-511.67K
Earnings yield
-0.03-0.08-0.050-1.05
Free cash flow yield
-0.03-0.07-0.04-0.160
Debt to equity
-7.15-2.30.130.10.17
Debt to assets
1.161.770.110.090.14
Net debt to EBITDA
7.030.34.392.040.42
Current ratio
3.152.1220.5307.39
Interest coverage
-2.340000
Income quality
0.930.870.9200.93
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.170.580.94032.33
Research and developement to revenue
1.112.963.770127.15
Intangibles to total assets
00000
Capex to operating cash flow
0.170.020.0200.12
Capex to revenue
-0.05-0.05-0.0700
Capex to depreciation
-4.62-0.88-1.180-2.61
Stock based compensation to revenue
0.020.050.1300
Graham number
2.859.0832.58015
ROIC
-2.18-0.9-1.17-0.4-1
Return on tangible assets
-0.11-0.53-0.10-0.5
Graham Net
-1.25-2.6919.115.743.12
Working capital
44.78M22.46M328.81M288.27M159.62M
Tangible asset value
-11.08M-34.55M309.86M271.79M176.16M
Net current asset value
-13.61M-37.08M306.51M261.47M155.42M
Invested capital
00000.02
Average receivables
00000
Average payables
02.55M2.4M877K3.59M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.670.69-0.120-0.58
Capex per share
-0.08-0.03-0.0500

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
0.71000.010.01
Net income per share
0-0.58-0.65-0.58-0.6
Operating cash flow per share
-0.44-0.62-0.38-0.661.67
Free cash flow per share
-0.3-0.68-0.57-0.681.92
Cash per share
2.185.655.064.373.81
Book value per share
6.435.885.254.74.16
Tangible book value per share
6.435.885.254.74.16
Share holders equity per share
6.435.885.254.74.16
Interest debt per share
0.030.110.110.10.1
Market cap
359.86M180.44M172.06M114.44M97.47M
Enterprise value
267.59M134.44M138.76M79.07M54.29M
P/E ratio
0-1.84-1.57-1.16-0.96
Price to sales ratio
11.9603.44K539.83249.93
POCF ratio
-19.23-6.87-10.55-4.081.38
PFCF ratio
-28.16-6.27-7.17-3.971.19
P/B Ratio
1.320.720.770.570.55
PTB ratio
1.320.720.770.570.55
EV to sales
8.902.78K372.98139.22
Enterprise value over EBITDA
0-5.59-5.2-3.34-1.98
EV to operating cash flow
-14.3-5.12-8.5-2.820.77
EV to free cash flow
-20.94-4.67-5.78-2.740.67
Earnings yield
0-0.14-0.16-0.22-0.26
Free cash flow yield
-0.04-0.16-0.14-0.250.84
Debt to equity
0.10.090.130.120.17
Debt to assets
0.090.080.110.110.14
Net debt to EBITDA
01.911.251.491.57
Current ratio
015.179.4610.537.39
Interest coverage
70000
Income quality
01.070.61.140.92
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0094.931.0312.25
Research and developement to revenue
00459.2688.9756.12
Intangibles to total assets
00000
Capex to operating cash flow
00.090.470.030.15
Capex to revenue
00-153.66-3.5428
Capex to depreciation
0-5.27-11.61-0.8-5.28
Stock based compensation to revenue
0030.668.13-12.23
Graham number
08.758.747.847.49
ROIC
0-0.15-0.16-0.18-0.25
Return on tangible assets
0-0.09-0.11-0.11-0.12
Graham Net
1.555.144.383.813.12
Working capital
288.27M238.17M205.17M182.38M159.62M
Tangible asset value
271.79M248.94M222.53M199.42M176.16M
Net current asset value
261.47M233.44M200.61M177.99M155.42M
Invested capital
00.020.020.020.02
Average receivables
00000
Average payables
1.63M1.3M4.13M4.36M5.1M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0-0.1-0.12-0.12-0.14
Capex per share
0-0.06-0.18-0.020.26

STTK Frequently Asked Questions

What is Shattuck Labs, Inc. stock symbol ?

Shattuck Labs, Inc. is a US stock , located in Austin of Tx and trading under the symbol STTK

What is Shattuck Labs, Inc. stock quote today ?

Shattuck Labs, Inc. stock price is $3.03 today.

Is Shattuck Labs, Inc. stock public?

Yes, Shattuck Labs, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap